The reduction in cardiomyocyte thickness and TGF-β1 immunoexpression suggests a potential protective role of Vinpocetine against fibrotic changes associated with diabetic cardiomyopathy (Figure 1). Here, TGFB1 is linked to diabetic cardiomyopathy.